Skip to content
Biodatica
Start free

BeiGene

Bengbu, Anhui

OncologyPhase IIListed · ONC

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase II trial registered: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

3mo agoTrial registeredApr 17, 2026Source filing (opens the source filing in a new tab)

Momentum

75no change

Momentum 75 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Mar 7, 2023

    Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: BeiGene · A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT05635708 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    May 6, 2022

    B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Unclassifiable, Richter's Transformation · RECRUITING · sponsor: BeiGene · Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

    ClinicalTrials.gov · NCT05294731 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources